Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in ...

Germany’s Formycon has decided today to prematurely terminate the Phase III trial (Lotus) for its biosimilar candidate FYB206 ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

BofA lowered the firm’s price target on Merck (MRK) to $112 from $118 and keeps a Buy rating on the shares. Q4 results were “decent,” but 2025 ...

Plus, the shipping pause could bring down Gardasil ... could arise from losing the exclusivity license of its other drug, Keytruda. The cancer therapy drug is one of Merck’s hero products ...

Shares of the New Jersey-based maker of oncology best-seller Keytruda fell over 10% mid-session despite the company posting beats on the top and bottom lines in the fourth quarter. Merck ...

In the longer term, Merck will have to adapt as its Keytruda patent is set to expire in 2028. Merck must figure out how to right the ship and turn its Gardasil sales around if it is to succeed.

Merck’s Gardasil sales fell short of expectations in the fourth quarter, and the company pulled its long-term target of $11 billion in Gardasil sales by 2030 in light of the decision to stop shipments ...

Its Gardasil program saw challenges, including a shipment pause to China ... is that Merck is facing patent loss of its key drug, Keytruda, in 2028. In 4Q24 alone, this drug generated $7.8 ...

Detailed price information for Compass Inc Cl A (COMP-N) from The Globe and Mail including charting and trades.